Abstract:e20526 Background: Immunotherapy with anti-programmed death 1 (PD-1) antibodies has revolutionized the treatment of metastatic and advanced non-small cell lung cancer (NSCLC). However, its application in neoadjuvant scenario has not been well established. Here, we conducted a retrospective study to evaluate the efficacy and safety of neoadjuvant chemo-immunotherapy for patients with potentially resectable NSCLC. Methods: We retrospectively reviewed clinical records of patients with potentially resectable NSCLC (stage IIIA-IIIB) with non-driver gene mutation. The patients underwent neoadjuvant chemo-immunotherapy between March 2019 and October 2020. The outcomes included R0 resection rate, pathologic complete responses (pCR), major pathologic responses (MPR) and safety. The data of whole exome sequencing (WES) and RNA-sequencing (RNA-seq) from tumor samples respectively collected at baseline and at surgery after neoadjuvant therapy were also evaluated. Results: Out of a total of 30 stage III NSCLC patients (29 males and 1 female) at a median age of 56.5 years (range: 46-74), 22 patients (73.3%) had squamous cell carcinoma. Patients received toripalimab/pembrolizumab and platinum-doublet chemotherapy for 2 cycles before surgery. The median duration from final treatment to surgery was 31 days (range: 22-82). One patient refused surgery, and 6 patients did not meet the surgical standards. 23 patients (76.7%) downstaged and reached the surgical standards after neoadjuvant therapy. Out of 23 patients with R0 surgical resection, 16 patients (69.6%) achieved MPR, including 7 patients (30.4%) achieved pCR. The median follow-up duration was 13 months (range: 2-21). As of Jan 20, 2021, no patient had relapsed or died. All grade and grade 3-4 treatment-related adverse events (TRAEs) were reported in 43.3% and 10% of patients, respectively. The most common grade 1-2 TRAEs were transaminase increased (13.3%) and hypothyroidism (16.7%). One patient delayed surgical treatment due to grade 4 transaminase increased. Baseline expression of type-I HLA molecule was lower in MPR/pCR group than that in non-MPR group (HLA-F: p = 0.052). After neoadjuvant therapy, the expression of HLA-F in MPR/pCR patients was significantly increased (p = 0.0047) while the expression of HLA-B in non-MPR patients was decreased (p = 0.032) compared to that of the baseline, suggesting that neoadjuvant therapy may potentially facilitate specific antigen presentation in the tumor tissues of patients with MPR/pCR. Conclusions: Neoadjuvant chemo-immunotherapy for potentially resectable NSCLC is a tolerable treatment with an improved surgical resection rate, MPR and pCR. Based on our findings, a prospective, single arm, phase II study of neoadjuvant toripalimab combined with platinum-doublet chemotherapy is currently being conducted (NCT04144608). Clinical trial information: NCT04324151.

Use of Pralsetinib as Neoadjuvant Therapy for Non-Small Cell Lung Cancer Patient With RET Rearrangement

A case of neoadjuvant targeted therapy with pralsetinib for locally advanced lung adenocarcinoma with RET fusion mutation

Pralsetinib treatment for multiple RET fusions in lung adenocarcinoma: a case report

Pralsetinib for the treatment of a RET-positive advanced non-small-cell lung cancer patient harboring both ANK-RET and CCDC6-RET fusions with coronary heart disease: a case report

Efficacy and safety of pralsetinib in patients with RET fusion positive non-small cell lung cancer: An observational real world study

Pralsetinib as neoadjuvant therapy for RET-Altered differentiated thyroid cancer: Two case reports

Neoadjuvant chemoimmunotherapy achieved a pathologic complete response in stage IIIA lung adenocarcinoma harboring RET fusion: a case report

Efficacy and safety of pralsetinib in patients with advanced RET fusion‐positive non–small cell lung cancer

JICC01.14 Efficacy and Safety of Pralsetinib in Chinese Patients with Advanced RET Fusion+ Non-Small Cell Lung Cancer after Platinum-Based Chemotherapy

MA02.02 Efficacy and Safety of Pralsetinib in Chinese Patients with Advanced RET Fusion+ Non-Small Cell Lung Cancer

Pralsetinib-associated pneumonia in RET fusion-positive non-small cell lung cancer

Patient with mediastinal carcinoma of unknown primary with RET fusion achieves durable response with RET inhibition

RET rearrangement as a mechanism of resistance to ALK-TKI in non-small cell lung cancer patient with EML4-ALK fusion: A case report

Erlotinib As Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Prospective, Single-Arm, Phase II Study

Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors.

The Treatment Status of Patients in NSCLC With RET Fusion Under the Prelude of Selective RET-TKI Application in China: A Multicenter Retrospective Research

Exposure‐Response Relationships for Pralsetinib in Patients with RET‐Altered Thyroid Cancer or RET Fusion‐Positive Nonsmall Cell Lung Cancer

Case report: Recurrent lung infections following treatment with pralsetinib for an elderly patient with RET-fusion positive NSCLC

The efficacy and safety of neoadjuvant anti-PD-1 inhibitor combined with platinum-based chemotherapy in patients with potentially resectable non-small cell lung cancer.

[Advances in the Treatment of RET Fusion-positive Advanced Non-small Cell Lung Cancer].

Neoadjuvant Crizotinib in Resectable Locally Advanced Non–Small Cell Lung Cancer with ALK Rearrangement